Clinical Trials Logo

Clinical Trial Summary

This research study is a randomized controlled trial (RCT) to test whether pharmacogenomics (PGx) testing for ADHD medications will help guide clinicians to choose medications and dosages for pediatric ADHD treatment that provide faster symptom relief, fewer or less severe side effects, improve patient quality of life, and lessen emotional stress for parents/guardians of the patients.


Clinical Trial Description

The study is a randomized controlled trial (RCT) of pediatric Attention Deficit Hyperactivity Disorder (ADHD) patients using an experimental group and a control group. The subjects in the experimental group will be administered a commercially available pharmacogenomics (PGx) test panel of 38 genes specifically related to drug metabolism rates and drug response. A subset of these genes are known to be involved in the pharmacokinetics and pharmacodynamics of ADHD medications.

The PGx test report indicates if there are genetic variants detected related to ADHD medications and consequently provides recommendations for the clinician on which medications and doses may be optimally effective. The control group is the "treatment as usual" (TAU) group whose subjects are treated with medications for ADHD based on the treating clinician's customary method(s) for selecting medications and doses.

The hypotheses to be tested are that PGx testing guidance will reduce the time it takes to reach a treatment regimen that improves patient symptom relief, reduces the frequency and severity of adverse drug reactions, improves patient quality of life, and reduces parental emotional stress. Additionally, since the test is performed using next-generation sequencing, we wish to tabulate relevant allele frequencies and use variant call files to discover previously unknown PGx genetic variants. ;


Study Design


Related Conditions & MeSH terms

  • Attention Deficit Disorder with Hyperactivity
  • Attention Deficit Disorders With Hyperactivity
  • Hyperkinesis

NCT number NCT03730870
Study type Interventional
Source Clinical and Translational Genome Research Institute, Inc.
Contact
Status Terminated
Phase N/A
Start date February 28, 2019
Completion date February 28, 2020

See also
  Status Clinical Trial Phase
Unknown status NCT01130467 - Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder Phase 4
Completed NCT00890240 - A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD) Phase 1
Completed NCT00890292 - A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD) Phase 1
Completed NCT00334880 - Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) Phase 3
Completed NCT00337285 - An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD) Phase 3
Recruiting NCT00372359 - Adverse Effect of Prolonged Methylphenidate Treatment on Cardiac Functions N/A